

Forskningsrapport DLCG, DLCR 2024 & Forskningscenter for Lungekræft

Ole Hilberg, Professor i lungemedicin ved SDU, formand for forskning i DLCG


I Scopus fremsøges 104 danske publikationer i 2024 indenfor lungecancer

- Presley C.J., Grogan M., Compston A., Hock K., Knauss B., Redder E., Arrato N.A., Lo S.B., Janse S., Benedict J., Hoyd R., Williams N., Hayes S., Wells-Di Gregorio S., Gill T.M., Allore H., Focht B., Quist M., Carbone D.P., Spakowicz D., Paskett E.D., Andersen B.L. **Resiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer**
- Hosseini S.A., Hajianfar G., Ghaffarian P., Seyfi M., Hosseini E., Aval A.H., Servaes S., Hanaoka M., Rosa-Neto P., Chawla S., Zaidi H., Ay M.R. **PET radiomics-based lymphovascular invasion prediction in lung cancer using multiple segmentation and multi-machine learning algorithms**
- Danielsen A.V., Andreassen J.J., Dinesen B., Hansen J., Petersen K.K., Duch K.S., Bisgaard J., Simonsen C., Arendt-Nielsen L **Pain trajectories and neuropathic pain symptoms following lung cancer surgery: A prospective cohort study**
- Ording A.G., Skjøth F., Poulsen L.Ø., Szejniuk W.M., Jakobsen E., Christensen T.D., Noble S., Overvad T.F. **Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung Cancer in Routine Clinical Practice: A Nationwide Cohort Study**

Fra Scopus 2024 (lung cancer + affil. Denmark

Documents by author


Compare the document counts for up to 15 authors.



Fra Scopus 2024 (lung cancer + affil. Denmark)

Documents by affiliation


Compare the document counts for up to 15 affiliations.



Fra Scopus 2024 (lung cancer + affil. Denmark)


Documents by country or territory

Compare the document counts for up to 15 countries/territories.




Fra Scopus 2024 (lung cancer + affil. Denmark

Documents by type




Fra Scopus 2024 (lung cancer + affil. Denmark

Documents by subject area




Fra Scopus 2024 (lung cancer + affil. Denmark)



Citations 2024

De Zuani M., Xue H., Park J.S., Dentro S.C., Seferbekova Z., Tessier J., Curras-Alonso S., Hadjipanayis A., Athanasiadis E.I., Gerstung M., Bayraktar O., Cvejic A.	2024	Single-cell and spatial transcriptomics analysis of non-small cell lung cancer	Nature Communications	50
Deng H., Zhou J., Chen H., Cai X., Zhong R., Li F., Cheng B., Li C., Jia Q., Zhou C., Petersen R.H., Rocco G., Brunelli A., Ng C.S.H., D'Amico T.A., Su C., He J., Liang W., Zhu B.	2024	Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study	International journal of surgery (London	48
Thiele M., Kamath P.S., Graupera I., Castells A., de Koning H.J., Serra-Burriel M., Lammert F., Ginès P.	2024	Screening for liver fibrosis: lessons from colorectal and lung cancer screening	Nature Reviews Gastroenterology and Hepatology	15

Dansk forskningscenter for lungekræft har registret følgende antal publikationer



Publikationer forskningscentret 2024


- Mette Kaasgaard, Uffe Bodtger, Søren T. Skou, Stephen Clift, Ole Hilberg, Daniel Bech Rasmussen, Anders Løkke. **Long-term Mette Kaasgaard, Uffe Bodtger, Søren T. Skou, Stephen Clift, Ole Hilberg, Daniel Bech Rasmussen, Anders Løkke. Long-term self-reported attendance in exercise training or lung choir and status of quality of life following initial pulmonary rehabilitation for COPD.** *Front. Rehabil. Sci., Sec. Pulmonary Rehabilitation*. Volume 5 – 2024. DOI: 10.3389/fresc.2024.1447765
- Mette Kaasgaard, Katarzyna Grebosz-Haring, Christina Davies, George Musgrave, J Matt McCrary, Stephen Clift. **Is it premature to formulate recommendations for policy and practice, based on culture and health research? A robust critique of the CultureForHealth (2022) report.** 2024. *Public Health* 12:1414070. doi: 10.3389/fpubh.2024.1414070)
- Stephen Clift, Arne Bathke, Helena Daffern, Christina Davies, Katarzyna Grebosz-Haring, Mette Kaasgaard, J Matt McCrary, George Musgrave, Leonhard Thun-Hohenstein. **WHO–LancetGlobal Series on health and the arts. The Lancet. Correspondence.** Volume 403, Issue 10434, P1335, April 06, 2024. DOI: 10.1016/S0140-6736(24)00246-0
- Clift, S, Grebosz-Haring, K, Thun-Hohenstein, L., Bathke, A., Kaasgaard, M. **The Need for Robust Critique of Arts and Health Research: The treatment of the Gene Cohen et al. (2006) paper on singing, wellbeing and health in subsequent evidence reviews.** *Arts and Health*. DOI: 10.1080/17533015.2023.2290075
- Gouliaev, A., Ali, F et al. **The Danish lung cancer registry: A nationwide validation study.** *Lung Cancer* 107527, 2023. <https://doi.org/10.1016/j.lungcan.2024.10752>
- Jørgensen, C. U., Løkke, A., Hjorth, P., Pisinger, C., & Farver-Vestergaard, I. (2024). **Barriers to implementation of smoking cessation support among healthcare professionals in the secondary healthcare sector: A qualitative and quantitative evaluation.** *Tobacco Prevention & Cessation*, 10, 12.
- Jensen KH, Persson G, Pøhl M, Frank MS, Hansen O, Schytte T, Kristiansen C, Knap M, Skovborg M, Vogelius IR, Friberg J. **Early Mortality After Curative-intent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer-A Population-based Cohort Study.** *Clin Oncol (R Coll Radiol)*. 2024 Sep 4:S0936-6555(24)00377-7. doi: 10.1016/j.clon.2024.08.015. Epub ahead of print. PMID: 39306558.
- Olloni A, Brink C, Lorenzen EL, Jeppesen SS, Hofmann L, Kristiansen C, Knap MM, Møller DS, Nygård L, Persson GF, Thing RS, Sand HMB, Diederichsen A, Schytte T. **Heart and Lung Dose as Predictors of Overall Survival in Patients self-reported attendance in exercise training or lung choir and status of quality of life following initial pulmonary rehabilitation for COPD.** *Front. Rehabil. Sci., Sec. Pulmonary Rehabilitation*. Volume 5 – 2024. DOI: 10.3389/fresc.2024.1447765

Publikationer forskningscentret 2024


- Olloni A, Lorenzen EL, Jeppesen SS, Diederichsen A, Finnegan R, Hoffmann L, Kristiansen C, Knap M, Milo MLH, Møller DS, Pøhl M, Persson G, Sand HMB, Sarup N, Thing RS, Brink C, Schytte T. An open source auto-segmentation algorithm for delineating heart and substructures – Development and validation within a multicenter lung cancer cohort. *Radiother Oncol.* 2024 Feb;191:110065. doi: 10.1016/j.radonc.2023.110065. Epub 2023 Dec 19. PMID: 38122851.
- Olloni A, Brink C, Lorenzen EL, Jeppesen SS, Hoffmann L, Kristiansen C, Knap MM, Møller DS, Nygård L, Persson GF, Thing RS, Sand HM, Diederichsen A, Schytte T. Does coronary artery calcium score have an impact on overall survival for locally advanced non-small cell lung cancer treated with definitive radiotherapy. *Radiother Oncol.* 2023 Aug;185:109719. doi: 10.1016/j.radonc.2023.109719. Epub 2023 May 29. PMID: 37257588. Olloni A, Lorenzen EL, Jeppesen SS, Diederichsen A, Finnegan R, Hoffmann L, Kristiansen C, Knap M, Milo MLH, Møller DS, Pøhl M, Persson G, Sand HMB, Sarup N, Thing RS, Brink C, Schytte T. An open source auto-segmentation algorithm for delineating heart and substructures – Development and validation within a multicenter lung cancer cohort. *Radiother Oncol.* 2024 Feb;191:110065. doi: 10.1016/j.radonc.2023.110065. Epub 2023 Dec 19. PMID: 38122851.
- Olloni A, Brink C, Lorenzen EL, Jeppesen SS, Hoffmann L, Kristiansen C, Knap MM, Møller DS, Nygård L, Persson GF, Thing RS, Sand HM, Diederichsen A, Schytte T. Does coronary artery calcium score have an impact on overall survival for locally advanced non-small cell lung cancer treated with definitive radiotherapy. *Radiother Oncol.* 2023 Aug;185:109719. doi: 10.1016/j.radonc.2023.109719. Epub 2023 May 29. PMID: 37257588.
- Wen SWC, Borg M, Timm S, Hansen TF, Hilberg O, Andersen RF. Methylated Cell-Free Tumor DNA in Sputum as a Tool for Diagnosing Lung Cancer-A Systematic Review and Meta-Analysis. *Cancers (Basel).* 2024 Jan 24;16(3):506. doi: 10.3390/cancers16030506. PMID: 38339257
- Gouliaev A, Berg J, Khalil AA, Dalton SO, Rasmussen TR, Christensen NL. Factors behind favorable long-term lung cancer survival in Norway compared to Denmark: a retrospective cohort study. *Eur Clin Respir J [Internet].* 2024 Dec 31;11(1). Available from: <https://www.tandfonline.com/doi/full/10.1080/20018525.2024.2414485>
- Henriksen MB, Hansen TF, Jensen LH, et al. A collection of multiregistry data on patients at high risk of lung cancer-a Danish retrospective cohort study of nearly 40,000 patients. *Transl Lung Cancer Res.* 2023;12(12):2392-2411. doi:10.21037/tlcr-23-495
- Ebrahimi, A., Henriksen, M.B.H., Brasen, C.L. et al. Identification of patients' smoking status using an explainable AI approach: a Danish electronic health records case study. *BMC Med Res Methodol* 24, 114 (2024). <https://doi.org/10.1186/s12874-024-02231-4>
- Issa MA, Clementsen PF, Laursen CB, Vilmann P, Christiansen IS, Crombag L, Bodtger U. Using the Endoscope for Endobronchial Ultrasound in the Esophagus. *J Vis Exp.* 2023 Nov 21;(201). doi: 10.3791/65741. PMID: 38078614.
- Issa, M. A., Clementsen, P. F., Laursen, C. B., Christiansen, I. S., Crombag, L., Vilmann, P., & Bodtger, U. (2024). Added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in diagnosing and staging of lung cancer. *European Clinical Respiratory Journal*, 11(1). <https://doi.org/10.1080/20018525.2024.2362995>
- AG Ording, TD Christensen, F Skjøth, S Noble, AA Højen, AL Mørkved, TB Larsen, RH Petersen, P Meldgaard, E Jakobsen, M Søggaard. Risk of venous thromboembolism in patients with stage III and IV non-small cell lung cancer: Nationwide descriptive cohort study. *Accepted Clinical Lung Cancer* 2024.
- AG Ording, F Skjøth, LØ Poulsen, WM Szejniuk, E Jakobsen, TD Christensen, S Noble, TF Overvad. Time toxicity of systemic anticancer therapy for metastatic lung cancer in routine clinical practice: descriptive nationwide cohort study. *Submitted Journal of Clinical Oncology* 2024.
- Gouliaev, A., Ali, F., Jakobsen, E., Dalton, S. O., Hilberg, O., Rasmussen, T. R., & Christensen, N. L. (2024). The Danish lung cancer registry: A nationwide validation study. *Lung Cancer*, 107527.
- Jørgensen, C. U., Løkke, A. Hjorth, P., Pisinger, C., Farver-Vestergaard, I., (2024) Barriers to implementation of smoking cessation support among healthcare professionals in the secondary healthcare sector. A qualitative and quantitative evaluation. *Tob. Prev. Cessation* 2024;10(February):

Scopus 2016-2025

Documents by year




Scopus 2016-2025



Scopus 2016-2025

Documents by funding sponsor


Compare the document counts for up to 15 funding sponsors.



Scopus 2025

Documents by author


Compare the document counts for up to 15 authors.



Scopus 2025

Documents by funding sponsor

Compare the document counts for up to 15 funding sponsors.



DLCR har i 2024 været udleveret data eller givet tilladelse til udlevering af data til følgende forskningsprojekter:

- ICU-behov og mortalitet efter VATS Jannie Bisgaard Stæhr
- Lung Cancer in Patients with Interstitial Lung Diseases: A populationbased matched cohort study Anne Ording
- Towards equity in cancer care: Improving access to cancer care in patients with ethnic minority background. Emma Neble Larsen
- Lung cancer screening – groups to be targeted in a Danish programme Maria del Pilar Fernandez Montejo
- Clinical outcomes of patients with diffuse large B-cell lymphoma and concomitant rheumatoid arthritis: nationwide Danish register-based cohort study Bergur Magnussen
- Brug af prædiktive markører ved lungecancer diagnostik Lærke Valsøe Bruhn
- Omkostninger ved kræftbehandling i sammenhæng med patienternes oplevede livskvalitet Henriette Tind Hasse
- Navigate – Individuel støtte til lungekræftbehandling Rikke Langballe Prognostiske biomarkører i lungekræft Anne Winther Larsen
- Incidens, prognose og de socioøkonomiske konsekvenser. Katrine Kristensen
- Sex-specific and Socioeconomic Variations in Cancer Incidence, Mortality and Late Complications Fie Andersen
- Spatial proteomics profiling of non-small cell lung cancer (NSCLC) biopsies - characterization of treatment resistance pathways and discovery of biomarker panels Peter Rindom Koffeldt
- Sarcopenia - an overlooked prognostic indicator in lung cancer Troels Lading

11.1 Liste over åbne protokoller for lungehindekkræft og lungekræft 2024

Dansk titel på forsøget	Kaldenavn for forsøget	Originaltitel på forsøget	Sted
Funktionel lungeundgåelse SPECT-vejledt strålebehandling af lungekræft	ASPECT	Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial	Aarhus Universitetshospital
Måling af behandlingseffekt via blodprøver ved avanceret ikke små-cellet lungekræft-et interventionsstudie	PRELUCA	Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer - a Randomized Interventional Study	- Nordsjællands Hospital - Næstved Sygehus
Navigate - Forbedring af overlevelse hos sårbare lungekræftpatienter	NAVIGATE	NAVIGATE - Improving Survival in Vulnerable Lung Cancer Patients Through Nurse Navigation, Symptom Monitoring and Exercise: Study Protocol for a Multicenter Randomized Controlled Trial	- Regionshospitalet Gødstrup - Sygehus Lillebælt - Vejle - Sjællands Universitetshospital, Roskilde - Sygehus Sønderjylland - Odense Universitetshospital - Aalborg Universitetshospital, Hobrovej
Sacituzumab tirumotecan (MK-2870) i kombination med pembrolizumab versus pembrolizumab alene i metastatisk ikke-småcellet lungekræft (NSCLC) med programmeret celledødsigand 1 (PD-L1) tumorandelsscore (TPS) ≥ 50% (MK-2870-007)	MK-2870-007-01	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)	- Aalborg Universitetshospital, Hobrovej - Regionshospitalet Gødstrup - Odense Universitetshospital
En undersøgelse til vurdering af sygdomsaktivitet og bivirkninger af intravenøs (IV) telisotuzumab vedotin sammenlignet med IV docetaxel hos voksne deltagere med tidligere behandlet ikke-pladecelle ikke-småcellet lungekræft (NSCLC)	M18-868	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	- Odense Universitetshospital - Sjællands Universitetshospital, Roskilde

Dansk titel på forsøget	Kaldenavn for forsøget	Originaltitel på forsøget	Sted
En undersøgelse af selpercatinib efter operation eller stråling hos deltagere med ikke-småcellet lungekræft (NSCLC)	LIBRETTO-432	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIa RET Fusion-Positive NSCLC	Odense Universitetshospital
En undersøgelse af af Trastuzumab Deruxtecan, som den første behandlingsmulighed for inoperabel, lokalt fremskreden/metastatisk ikke-småcellet lungekræft med HER2-mutationer	DESTINY-Lung04	An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	Sygehus Lillebælt - Vejle
Et forsøg som skal undersøge, hvor godt BAY 2927088 virker, og hvor sikker den er sammenlignet med standardbehandling, hos deltagere, der har fremskreden ikke-småcellet lungekræft (NSCLC) med mutationer i generne af human epidermal vækstfaktor receptor 2 (HER2)	SOHO-02	A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.	- Rigshospitalet - Aarhus Universitetshospital - Odense Universitetshospital - Aalborg Universitetshospital, Hobrovej
LIVELUNG - Virkningen af CGA hos patienter diagnosticeret med lokaliseret NSCLC behandlet med SBRT	Livelung	LIVELUNG - Impact of CGA on QoL, Overall Survival and the Need for Admission in Patients Diagnosed With Localized NSCLC Treated With SBRT - a National Randomized Study	- Sygehus Lillebælt - Aarhus Universitetshospital - Odense Universitetshospital
En undersøgelse, der evaluerer effektiviteten og sikkerheden af divarasib versus sotorasib eller adagrasib hos deltagere med tidligere behandlet KRAS G12C-positiv avanceret eller metastatisk ikke-småcellet lungekræft	Krascendo 1	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer	- Herlev Hospital - Aarhus Universitetshospital - Regionshospitalet Gødstrup
En undersøgelse af V940 Plus Pembrolizumab (MK-3475) versus placebo plus Pembrolizumab hos deltagere med ikke-småcellet lungekræft (V940-002)	V940-002	A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus	- Rigshospitalet - Odense Universitetshospital

Dansk titel på forsøget	Kaldenavn for forsøget	Originaltitel på forsøget	Sted
		Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTERpath-002)	
MEDI5752 i kombination med carboplatin plus pemetrexed ved inoperabelt pleuralt mesoteliom	eOLVE-Meso	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eOLVE-Meso)	• Aarhus Universitetshospital • Rigshospitalet
En undersøgelse, der evaluerer Sotorasib Platinum Doublet-kombination versus Pembrolizumab Platinum Doublet-kombination som en frontlinjeterapi hos deltagere med fase IV eller avanceret stadium IIIB/C ikke-pladecellede ikke-småcellet lungekræft (CodeBreak 202)	CodeBreak 202	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreak 202)	• Regionshospitalet Gødstrup • Rigshospitalet • Aarhus Universitetshospital

De kommende år

- Mange spændende projekter i DFLK kommer til at blive afsluttet.
- Målsætningen for 50 % 5års overlevelse i 2030 forfølges
- Optimisme... ses også i internationale publicationer
- KB og NNF har givet penge til nye projekter primært inden for diagnostik
- Ændring i Novo Nordisk Fonden gør, at vi (DFLK) bør søge på ny
- DFLK har næste årsmøde i oktober